DESTINY-Breast04: Trastuzumab Deruxtecan in HR+/HER2-Low Metastatic Breast Cancer

Opinion
Video

Breast cancer specialists review key efficacy and safety data from the DESTINY-Breast04 trial investigating trastuzumab deruxtecan in patients with HR+/HER2-low metastatic breast cancer.

Video content above is prompted by the following questions:

  • Please review key efficacy and safety data from the DESTINY-Breast04 trial, evaluating trastuzumab deruxtecan (T-DXd) in patients with HR+, HER2-low metastatic breast cancer.
    • What are the clinical implications of these data in your practice?
    • What notable adverse events (AEs) have you observed in your practice?
    • What mitigation strategies have been implanted in your practice to combat AEs of special interest?
Recent Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content